Table 2.

Progression of myelodysplasia patient 1

Time from Primary Diagnosis Karyotype FISH ResultsClinical Status TP53 Status
0 mo  46, XX, t(15;17)(q22;q21)  APL t(15;17)  Presentation  Normal 
6 mo  46, XX   Complete Remission  Normal  
21 mo ND  13% der(5;17)  Complete Remission  Normal  
24 mo ND  33% der(5;17)  Complete Remission  Normal  
29 mo 45, XX, −5, add(17)(p11.2)[6]  43% der(5;17)  Complete Remission  Normal  
32 mo  45, XX, −5, add(17)(p11.2)[19] 74% der(5;17)  Complete Remission  Normal/Mutant  
35 mo 45, XX, −5, add(17)(p11.2)[5] 42-45, XX, chromosomes exhibiting shared abnormalities consisting of −3, −5, add(6)(p25), −7, −14, −15, add(17)(p11.2), +2mar[15]  95% der(5;17) Relapse MDS 9% blasts  Mutant 
Time from Primary Diagnosis Karyotype FISH ResultsClinical Status TP53 Status
0 mo  46, XX, t(15;17)(q22;q21)  APL t(15;17)  Presentation  Normal 
6 mo  46, XX   Complete Remission  Normal  
21 mo ND  13% der(5;17)  Complete Remission  Normal  
24 mo ND  33% der(5;17)  Complete Remission  Normal  
29 mo 45, XX, −5, add(17)(p11.2)[6]  43% der(5;17)  Complete Remission  Normal  
32 mo  45, XX, −5, add(17)(p11.2)[19] 74% der(5;17)  Complete Remission  Normal/Mutant  
35 mo 45, XX, −5, add(17)(p11.2)[5] 42-45, XX, chromosomes exhibiting shared abnormalities consisting of −3, −5, add(6)(p25), −7, −14, −15, add(17)(p11.2), +2mar[15]  95% der(5;17) Relapse MDS 9% blasts  Mutant 

ND = not done; APL = acute promyelocytic leukemia; MDS = myelodysplasia.

Close Modal

or Create an Account

Close Modal
Close Modal